Medical device manufacturer Integra LifeSciences Holdings Corp. was on the receiving end of a warning letter from the U.S. Food & Drug Administration last week, in which it was cited over concerns relating to process validations, corrective and preventative actions, as well as document controls, at its Añasco plant.